Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1957 of 6351
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control CompletedThe purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New combo therapy offers hope for Tough-to-Treat leukemia
Disease control OngoingThis phase II trial studies the effects of venetoxlax in combination with decitabine and cedazuridine in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as venetoclax and decitabin…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New program aims to boost mental health in prostate cancer survivors
Symptom relief Recruiting nowEach year over 20,000 men are diagnosed with prostate cancer in Canada with the majority undergoing some form of treatment option. Radical prostatectomy and/or radiation therapy are common procedures that are effective in the treatment of prostate cancer. However, they typically …
Sponsor: Gabriela Ilie • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Electric brain implant offers new hope for untreatable depression
Symptom relief Recruiting nowThis research study is designed to test if electrical stimulation of the surface of the brain in the frontal region will help treat depressive symptoms. Participants receive intermittent electrical stimulation to the brain, which involves surgically placing electric leads in betw…
Sponsor: University of Minnesota • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
Disease control Stopped earlyThis trial offers support and assistance to patients wishing to quit smoking in order to increase the success rate of smoking cessation and all the benefits associated with it. Patients will be monitored by a tobacco specialist and will be able to benefit from one or more therapi…
Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control CompletedThe purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Tiny lung artery implant aims to unburden failing hearts
Disease control Recruiting nowContraBand™ is a transcatheter constriction device which is implanted in the left and right branch pulmonary arteries. The effect is achieved by causing a local reduction in the internal diameters of the branch PAs, resulting in a lower distal systolic pulmonary artery pressure (…
Sponsor: Restore Medical Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Could a cancer drug slow lung scarring? new trial tests anlotinib for IPF
Disease control OngoingThis is an exploratory Phase 2 study evaluating the use of Anlotinib hydrochloride capsules for the treatment of IPF/PF-ILDs, with forced vital capacity (FVC) as the primary efficacy endpoint.
Phase 2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New antibody drug takes on tough cancers
Disease control OngoingThis is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug plozasiran aims to lower high fats in the blood
Disease control CompletedParticipants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluated for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout…
Phase 2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Money and support groups boost HIV care in kenya
Disease control CompletedThis study seeks to use a group-based microfinance/internal lending model to develop social capital among people with HIV in Kenya. This will create a context to deliver validated curriculum targeting intimate partner violence, positive parenting, agriculture, small business entr…
Sponsor: The University of Texas Medical Branch, Galveston • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New combo shows promise for tough head and neck cancers
Disease control OngoingThe primary hypothesis is that the objective response rate (ORR) with nab-paclitaxel and nivolumab will be significantly higher than the historical control (ORR 30%). The KEY secondary hypothesis is that the median PFS with nab-paclitaxel and nivolumab will be significantly long…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail shows promise for tough blood cancers
Disease control CompletedThe purpose of the study is to determine the safety and tolerability of pembrolizumab/vibostolimab (MK-7684A) in hematological malignancies. This study will also evaluate the overall response rate (ORR), the duration of response (DOR), and disease control rate (DCR) following adm…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a smartphone app boost CPAP therapy for sleep apnea?
Disease control CompletedObstructive sleep apnea syndrome (OSA) is a common condition associated with major repercussions such as excessive daytime sleepiness and impaired quality of life as well as metabolic and cardiovascular complications. Continuous positive airway pressure (CPAP) remains the treatme…
Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can balance training with electrical stimulation stop falls in spinal cord injury?
Disease control CompletedFalls are a health crisis that cost health care systems billions of dollars/year. This crisis is especially relevant for individuals living with incomplete spinal cord injury (iSCI); 78% fall at least once annually. In able-bodied individuals, falls are prevented by taking reacti…
Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Personalized support after first psychosis: a 3-Year test
Disease control Recruiting nowThe study investigators hypothesize that the intervention of case managers specifically trained in case management of early psychosis will change the paradigm of care of a first psychotic episode from the current organization of the care system. Indeed, the creation of specific s…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New study aims to bring autism therapy to more kids through public system
Symptom relief OngoingDespite strong consensus that early, specialized intervention for children with autism spectrum disorder (ASD) can have a dramatic impact on outcomes, the public health system's capacity to provide such services is severely challenged by the rapid rise in ASD prevalence. The goal…
Sponsor: Rush University Medical Center • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
Head-to-Head: which biologic works best for nasal polyps and asthma?
Disease control CompletedPrimary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives * To evaluate the efficacy of dupilumab in improving chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms at Week …
Phase 4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control CompletedThe main purpose of this study is to evaluate the safety, tolerability, and recommended phase 2 target dose of tarlatamab in combination with AMG 404.
Phase 1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Engineered immune cells take on tough gynecologic tumors
Disease control Recruiting nowThis study is to investigate the safety and efficacy of signal switch receptor modified TIL (GC201 TIL) in patients with advanced gynecologic tumors. Autologous TILs from tumor resections or biopsies are first gene modified(TGF-β receptor or PD-1 gene modified TILs which could tr…
Early phase 1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC